Role of routine human papillomavirus subtyping in cervical screening

被引：9

作者：

Goodman, A ^{[1
]}

机构：

[1] Massachusetts Gen Hosp, Div Gynecol Oncol, Boston, MA 02114 USA

来源：

CURRENT OPINION IN OBSTETRICS & GYNECOLOGY | 2000年 / 12卷 / 01期

关键词：

D O I：

10.1097/00001703-200002000-00002

中图分类号：

R71 [妇产科学];

学科分类号：

100211 ;

摘要：

Human papillomavirus testing has been evaluated as an adjunct to cervical cytologic screening. There is a well-established association between high-risk malignant subtypes of human papillomavirus infection and the development of neoplastic change. Although human papillomavirus infection is a necessary condition for malignant transformation, it is not a sufficient condition. Multiple cofactors are necessary for progression to dysplasia and then to invasive cervical cancer. Because of the multifactorial nature of malignant transformation, current methods of human papillomavirus testing do not add sufficient predictive and diagnostic information over that obtained by cytology and colposcopic biopsy to warrant routine clinical use. (C) 2000 Lippincott Williams & Wilkins.

引用

页码：11 / 14

页数：4

共 42 条

[1] Is human papillomavirus testing an effective triage method for detection of high-grade (grade 2 or 3) cervical intraepithelial neoplasia? [J].

Adam, E ;

Kaufman, RH ;

Berkova, Z ;

Icenogle, J ;

Reeves, WC .

AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1998, 178 (06) :1235-1241

[2]

*AM COLL OBST GYN, 1993, AUG ACOG TECHN B, V183

[3] Prediction of recurrent and residual cervical dysplasia by human papillomavirus detection among patients with abnormal cytology [J].

Bollen, LJM ;

Tjong-A-Hung, SP ;

van der Velden, J ;

Mol, BW ;

ten Kate, FWJ ;

ter Schegget, J ;

Bleker, OP .

GYNECOLOGIC ONCOLOGY, 1999, 72 (02) :199-201

[4] PREVALENCE OF HUMAN PAPILLOMAVIRUS IN CERVICAL-CANCER - A WORLDWIDE PERSPECTIVE [J].

BOSCH, FX ;

MANOS, MM ;

MUNOZ, N ;

SHERMAN, M ;

JANSEN, AM ;

PETO, J ;

SCHIFFMAN, MH ;

MORENO, V ;

KURMAN, R ;

SHAH, KV ;

ALIHONOU, E ;

BAYO, S ;

MOKHTAR, HC ;

CHICAREON, S ;

DAUDT, A ;

DELOSRIOS, E ;

GHADIRIAN, P ;

KITINYA, JN ;

KOULIBALY, M ;

NGELANGEL, C ;

TINTORE, LMP ;

RIOSDALENZ, JL ;

SARJADI ;

SCHNEIDER, A ;

TAFUR, L ;

TEYSSIE, AR ;

ROLON, PA ;

TORROELLA, M ;

TAPIA, AV ;

WABINGA, HR ;

ZATONSKI, W ;

SYLLA, B ;

VIZCAINO, P ;

MAGNIN, D ;

KALDOR, J ;

GREER, C ;

WHEELER, C .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1995, 87 (11) :796-802

[5]

Chua KL, 1996, CANCER, V77, P121, DOI 10.1002/(SICI)1097-0142(19960101)77:1<121::AID-CNCR20>3.0.CO

[6]

2-6

[7] Hybrid Capture II-based human papillomavirus detection, a sensitive test to detect in routine high-grade cervical lesions: a preliminary study on 1518 women [J].

Clavel, C ;

Masure, M ;

Bory, JP ;

Putaud, I ;

Mangeonjean, C ;

Lorenzato, M ;

Gabriel, R ;

Quereux, C ;

Birembaut, P .

BRITISH JOURNAL OF CANCER, 1999, 80 (09) :1306-1311

[8] Cervicography and HPV DNA testing as triage criteria for patients with abnormal Pap smear [J].

Costa, S ;

Sideri, M ;

Bucchi, L ;

Schettino, F ;

Maini, I ;

Spinaci, L ;

Bovicelli, L ;

Terzano, P .

GYNECOLOGIC ONCOLOGY, 1998, 71 (03) :404-409

[9] HUMAN PAPILLOMAVIRUS DNA IN WOMEN WITHOUT AND WITH CYTOLOGICAL ABNORMALITIES - RESULTS OF A 5-YEAR FOLLOW-UP-STUDY [J].

DEVILLIERS, EM ;

WAGNER, D ;

SCHNEIDER, A ;

WESCH, H ;

MUNZ, F ;

MIKLAW, H ;

HAUSEN, HZ .

GYNECOLOGIC ONCOLOGY, 1992, 44 (01) :33-39

[10]

Fait G, 1998, GYNECOL ONCOL, V70, P319, DOI 10.1006/gyno.1998.5115

← 1 2 3 4 5 →